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Snake venom is a natural substance that contains numerous bioactive proteins and peptides, 
nearly all of which have been identified over the last several decades. In this study, we subjected 
snake venom to enzymatic hydrolysis to identify previously unreported bioactive peptides. The 
novel peptide ACH-11 with the sequence LTFPRIVFVLG was identified with both FXa inhibition 
and anti-platelet aggregation activities. ACH-11 inhibited the catalytic function of FXa towards its 
substrate S-2222 via a mixed model with a Ki value of 9.02 μ M and inhibited platelet aggregation 
induced by ADP and U46619 in a dose-dependent manner. Furthermore, ACH-11 exhibited potent 
antithrombotic activity in vivo. It reduced paralysis and death in an acute pulmonary thrombosis 
model by 90% and attenuated thrombosis weight in an arterio-venous shunt thrombosis model by 
57.91%, both at a dose of 3 mg/kg. Additionally, a tail cutting bleeding time assay revealed that ACH-
11 did not prolong bleeding time in mice at a dose of 3 mg/kg. Together, our results reveal that ACH-
11 is a novel antithrombotic peptide exhibiting both FXa inhibition and anti-platelet aggregation 
activities, with a low bleeding risk. We believe that it could be a candidate or lead compound for new 
antithrombotic drug development.
Thrombosis is a leading cause of morbidity and mortality throughout the world and plays a pivotal role 
in the pathogenesis of numerous cardiovascular disorders, including acute coronary syndrome, myo-
cardial infarction, unstable angina, deep-vein thrombosis and pulmonary embolism1. Blood clotting in 
response to vascular injury requires the activation of zymogens in the coagulation cascade, in which 
thrombin and FXa are key players. FXa, a trypsin-like serine protease, functions at the convergence of 
the extrinsic and intrinsic coagulation pathways. Thus, it plays a central role in the coagulation cascade 
by catalyzing the production of thrombin, leading to further clot formation and wound closure2.
The search for thrombin inhibitors has been the focus of early antithrombotic drug development 
efforts because thrombin plays multiple roles in normal coagulation, including catalyzing the cleavage 
of fibrinogen to fibrin, catalyzing the formation of FVa and FVIIIa, and activating platelets3. In clinical 
trials, direct thrombin inhibitors did not block the continuous production of thrombin from prothrom-
bin, which is the most abundant procoagulant zymogen in the coagulation cascade4–6. The high levels of 
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thrombin inhibition necessary to produce an effective antithrombotic action in vivo can lead to unaccept-
able levels of anticoagulation and an accompanying risk of hemorrhage. In contrast, inhibition of FXa, a 
component of the prothrombinase complex that converts prothrombin to thrombin, would prevent the 
continuous production of thrombin while maintaining the basal activity of thrombin necessary for pri-
mary hemostasis7. Thus, FXa has emerged as a more attractive target for the development of new antico-
agulants in recent years8. Among the numerous natural FXa inhibitors, tick anticoagulant peptide (TAP)9 
and antistasin (ATS)10 have been studied in various arterial and venous thrombosis models, as well as in 
a model of disseminated intravascular coagulation (DIC). The results have unequivocally demonstrated 
that the specific inhibition of FXa is superior to that achieved by heparin or direct thrombin inhibitors11.
Some peptides, which are inactive within the parent protein, can be released by enzymatic hydrolysis 
and exhibit diverse bioactivities. Thus, a number of bioactive peptides have been obtained by enzymatic 
methods, and those peptides include angiotensin-converting enzyme (ACE) inhibitory peptide from tuna 
frame protein hydrolysate12, antioxidant peptide from grass carp muscle hydrolysate13, antimicrobial pep-
tide from anchovy hydrolysate14, and anticoagulant peptide from scorpion protein and goby muscle pro-
tein hydrolysate15,16. However, studies of the hydrolysis of animal venoms are rare. Therefore, the goal of 
the present study was to hydrolyze snake venom, which contains numerous antithrombotic proteins and 
peptides, in order to release potential anti-FXa peptides. Bioassay-directed chromatographic separation 
was carried out in the presence of FXa inhibiting activity, and a novel peptide demonstrating both FXa 
inhibition and anti-platelet aggregation activities was obtained. Its antithrombotic activity was further 
characterized in animal models. To the best of our knowledge, this is the first report of the enzymatic 
hydrolysis of snake venom and the discovery of a new peptide demonstrating dual inhibition of FXa and 
platelet aggregation.
Results
Preparation of Agkistrodon acutus venom hydrolysates. Enzymes have specific cleavage posi-
tions within polypeptide chains. To select suitable proteases, Agkistrodon acutus venom was inde-
pendently hydrolyzed with pepsin, papain, neutrase and alcalase using a batch reactor. As shown in 
Fig. 1a, the FXa inhibitory activities of Agkistrodon acutus venom hydrolysates increased after digestion 
with various proteolytic enzymes during the first 3 or 4 hours and then decreased, which may result from 
excessive hydrolysis that leads to a decrease in bioactive peptide content in the hydrolysate. Amongst 
the four enzymes examined, neutrase digest for 3 h resulted in the highest FXa inhibitory activity, from 
which the maximum inhibitory rate of FXa by the hydrolysate reached 38.37 ± 0.58% (mean ± SD, n = 3) 
at a concentration of 5 mg/mL. Thus, the Agkistrodon acutus venom hydrolysate produced by neutrase 
treatment for 3 h was selected for further purification.
Purification of FXa inhibitory peptide from Agkistrodon acutus venom hydrolysates. The 
purification procedure consisted of a combination of gel filtration and reverse-phase chromatography, 
guided by monitoring FXa inhibitory activity. The neutrase hydrolysate was dissolved in distilled water 
and was applied to a gel filtration column (2.6 × 100 cm) packed with Sephadex G-50 and equilibrated 
with distilled water. As reported in Fig. 1b, five fractions designated A-E were isolated. Each was collected 
and independently tested for FXa inhibitory activity. The fraction C, which displayed the strongest inhib-
itory effect on the amidolytic activity of FXa (Fig.  1c), was further purified by RP-HPLC on a Hedera 
ODS-2 column (20 × 250 mm) equilibrated with 10% acetonitrile containing 0.1% TFA. The elution pro-
file obtained on a linear gradient of 10–30% acetonitrile containing 0.1% TFA included eight fractions 
designated C1-C8 (Fig. 1d). The fraction C4 displayed the highest FXa inhibitory activity (Fig. 1e) and 
was collected and lyophilized. The purity of fraction C4 was greater than 96%, as determined on an ana-
lytical C18 column (4.6 × 250 mm) using a Shimadzu LC-20AT HPLC system (Supplementary Fig. S1).
Determination of the molecular mass and peptide sequence. The molecular mass of the puri-
fied fraction C4 was determined using ESI-MS. The m/z values of the single charged ions ([M + H]+) 
and double charged ions ([M + 2H]2+) were 1261.77 and 631.39 Da, respectively (Fig.  2a). Thus, the 
molecular mass of the peptide was 1260.77 Da. The amino acid sequence of this peptide was identified as 
LTFPRIVFVLG by tandem mass spectrometry (MS/MS) (Fig. 2b), which is consistent with the observed 
mass from ESI-MS.
In order to test its biological activity, ACH-11 was chemically synthesized using the Fmoc solid-phase 
synthesis method and was then purified by HPLC on a Kromasil Semipreparative C18 column 
(250 × 10 mm). The purity of ACH-11 was greater than 98% (Supplementary Fig. S2).
ACH-11 is a novel potent FXa inhibitor. ACH-11 inhibited the catalytic activity of FXa towards its 
substrate S-2222 in a dose-dependent manner, and the Michaelis-Menten plot is shown in Fig. 3. Plots of 
its inhibition activity were obtained for different concentrations of ACH-11 and showed a slope of 0.376 
for the control without ACH-11, a slope of 0.528 for 5 μ M, and a slope of 0.698 for 10 μ M.
The Lineweaver-Burk plots in Fig. 3 (inset) showing inhibition of FXa by ACH-11 indicated a mixed 
type of inhibition. A decrease in the Vmax value with a subsequent increase in the Km value of FXa 
towards S-2222 in the presence of ACH-11 was observed. The Ki value for FXa inhibition towards S-2222 
by ACH-11 was determined to be 9.02 μ M.
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ACH-11 exerted anticoagulation activity both ex vivo and in vivo. To evaluate the effects of 
ACH-11 on coagulation parameters ex vivo, we measured the influence of the peptide on the acti-
vated partial thromboplastin time (aPTT) and prothrombin time (PT). Intravenous pre-administration 
of ACH-11 to rats significantly increased aPTT in a dose-dependent manner at doses ranging from 
0.33 to 3 mg/kg. As shown in Fig. 4, aPTT and PT in the vehicle-treated group were 20.58 ± 0.33 s and 
16.18 ± 0.62 s (mean ± SD, n = 3), respectively. In the ACH-11-treated groups, aPTT increased signifi-
cantly to 158.05 ± 6.89 s, 104.35 ± 4.98 s and 62.20 ± 3.32 s at doses of 3, 1 and 0.33 mg/kg (P < 0.0001 
versus vehicle), respectively. Even at the highest test dose of 3 mg/kg, PT did not significantly increase 
when compared to the vehicle group (P > 0.05).
Figure 1. Selection of enzymatic hydrolysis conditions and bioassay-directed chromatographic 
separation of the FXa inhibitory peptide. (a) FXa inhibitory activities of Agkistrodon acutus venom 
hydrolysates obtained by treatment with pepsin, papain, neutrase and alcalase at 1, 2, 3, 4, 8, 12 h intervals. 
(b) Agkistrodon acutus venom hydrolysate produced by neutrase (3 h) was separated on a gel filtration 
column packed with Sephadex G-50 (2.6 × 100 cm). The hydrolysate was eluted by distilled water at a flow 
rate of 0.6 mL/min, collecting fractions of 3.6 mL. (c) The FXa inhibitory activities of fractions A-E. (d) 
Fraction C was separated on a Hedera ODS-2 column (20 × 250 mm). (e) The FXa inhibitory activities of 
fractions C1-C8. Data are presented as the mean ± SD (n = 3).
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In in vivo clotting time experiments, ACH-11 significantly prolonged blood clotting time in a 
dose-dependent manner (P < 0.0001 versus vehicle, n = 10) at doses ranging from 0.33 to 3 mg/kg. This 
indicated that ACH-11 had anticoagulant effects in vivo (Supplementary Fig. S3).
ACH-11 inhibited ADP- and U46619-induced rabbit platelet aggregation in vitro. To study 
the effect of ACH-11 on platelet aggregation, we used rabbit platelet-rich plasma (PRP) induced with 
Figure 2. The peptide obtained from hydrolysate was identified by ESI-MS/MS mass spectrometry. (a) 
Mass spectrum of the C4 fraction. (b) MS/MS spectrum of ion m/z 1261.77. By manual calculation, the 
sequence of this peptide is displayed with the fragment ions observed in the spectrum. For clarity, only b 
and y ions are labeled.
Figure 3. Kinetic activity of ACH-11 to FXa in vitro. Lineweaver-Burk plot (inset) for ACH-11 kinetics 
in PBS at pH 8.34 and 37 °C with mixed inhibition in the presence of different concentrations of ACH-11: 
0 μ M (slope of 0.376), 5 μ M (slope of 0.528) and 10 μ M (slope of 0.698). The plots represent the mean of 3 
independent measurements.
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various agonists as an in vitro model. The results showed that ACH-11 selectively inhibited platelet aggre-
gation induced by different agonists. As shown in Fig. 5, ACH-11 inhibited ADP (10 μ M)- and U46619 
(6 μ M)-induced platelet aggregation in a dose-dependent manner, with IC50 values of 204.24 μ M (95% 
CI, 185.36–225.02 μ M) and 467.57 μ M (95% CI, 415.62–525.95 μ M), respectively. At 1 mg/mL, the pep-
tide inhibited ADP (10 μ M)- and U46619 (6 μ M)-induced rabbit platelet aggregation by 76.69 ± 0.99% 
and 60.46 ± 3.08% (mean ± SD, n = 3), respectively, while ACH-11 exerted only weak inhibitory effects 
on thrombin (3 U/mL)- and collagen (2.5 μ g/mL)-induced platelet aggregation. Even at 1 mg/mL, the 
peptide showed only 10.46 ± 4.12% and 2.44 ± 1.65% inhibitory rates (mean ± SD, n = 3) against throm-
bin (3 U/mL)- and collagen (2.5 μ g/mL)-induced rabbit platelet aggregation, respectively.
ACH-11 inhibited ADP-induced acute pulmonary thrombosis in mice and arterio-venous shunt 
thrombosis in rats in vivo. To examine whether ACH-11 exerted antithrombotic effects in vivo, the 
peptide was challenged in an acute pulmonary thrombosis model in mice. Aspirin, which is a clinical 
Figure 4. ACH-11 prolonged ex vivo plasma coagulation time. Thirty minutes after the administration of 
ACH-11 (3, 1 and 0.33 mg/kg, i.v.) and the vehicle, blood was taken from the inferior vena cava of rats, and 
platelet-poor plasma (PPP) was then obtained by centrifugation at 2,000 g for 10 min at room temperature 
to test ex vivo PT and aPTT. Data are presented as the mean ± SD of three independent experiments. 
****P < 0.0001 versus vehicle, analyzed by one-way ANOVA, followed by the Tukey multiple comparison test.
Figure 5. ACH-11 inhibited ADP- and U46619-induced rabbit platelet aggregation in vitro. PRP was 
preincubated for 5 min with different concentrations of ACH-11 (0.1, 0.25, 0.5 and 1 mg/mL) or the vehicle. 
Platelet aggregation was initiated with ADP (10 μ M), U46619 (6 μ M), thrombin (3 U/mL) or collagen (2.5 μ g/
mL). Data are the mean ± SD (n = 3), ****P < 0.0001 and *P < 0.05 versus vehicle, analyzed by one-way 
ANOVA, followed by the Tukey multiple comparison test.
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anti-thrombosis medicine that acts as a selective COX-1 inhibitor, was used as a positive control. In this 
model, small thrombi formed by intravenous injection of ADP (300 mg/kg) occluded pulmonary vessels, 
resulting in paralysis or death of the mice. These results showed that intravenous pre-administration of 
the peptide protected against lethality in a dose-dependent manner (Table 1). Administration of the pep-
tide at 3 mg/kg (i.v.) significantly prevented paralysis and death, with a protection rate of 90%. Moreover, 
the peptide showed a more potent effect than aspirin, as aspirin showed only 80% protection rate with 
a 6-fold higher dose of 20 mg/kg.
The effect of ACH-11 on thrombus formation was further evaluated in the rat arterio-venous shunt 
thrombosis model. As illustrated in Fig. 6, ACH-11 inhibited thrombosis formation in a dose-dependent 
manner, while the anti-thrombosis ability of ACH-11 was better than that of aspirin. After administration 
of ACH-11 (i.v.) at 0.33, 1 and 3 mg/kg, thrombus weight was reduced by 14.93 ± 3.57%, 40.6 ± 2.75%, and 
57.91 ± 2.80% (mean ± SEM, n = 6), respectively. However, when given 20 mg/kg of aspirin, the weight of 
the thrombus formed inside the arterio-venous shunt tube was reduced by 59.10 ± 2.98% (mean ± SEM, 
n = 6), indicating that a 6-fold higher dose of aspirin produced the same effect as ACH-11.
ACH-11 exhibited a low bleeding risk in mice. To assess the bleeding risk incurred by ACH-11, 
we measured the bleeding time of ACH-11-treated mice by a mice tail cutting assay at ACH-11 con-
centrations of 1, 3 and 9 mg/kg, representing three times the doses used for the in vivo anti-thrombotic 
studies. Aspirin (9 mg/kg)-treated mice served as the positive control. As shown in Fig. 7, a slight prolon-
gation of the bleeding time was observed at 9 mg/kg of ACH-11 (14.01 ± 1.88 min, mean ± SD, n = 10), 
shorter than with aspirin (17.03 ± 2.86 min, mean ± SD, n = 10) treatment at the same dose. At doses 
of 3 and 1 mg/kg, the efficient dosages required to avoid thrombus formation and to protect against 
paralysis or death in mice, ACH-11 did not significantly prolong the bleeding time (11.73 ± 2.68 min 
Samples










Aspirin 20 2/10 80** 0.0055
ACH-11 0.33 7/10 30 0.5820
1 4/10 60* 0.0198
3 1/10 90** 0.0011
Table 1. ACH-11 inhibited ADP-induced acute pulmonary thrombosis in mice. Note: **P < 0.01, *P < 0.05 
versus vehicle, n = 10 (χ 2 test).
Figure 6. ACH-11 inhibited arterio-venous shunt thrombosis in rats in vivo. After the administration of 
ACH-11 (0.33, 1 and 3 mg/kg), aspirin and the vehicle, rats were anesthetized by intraperitoneal injection of 
chloral hydrate (350 mg/kg), and an arterio-venous shunt tube (12 cm, containing 10-cm long of 4 braided 
silk thread) was installed between the right carotid artery and left jugular vein of each rat. After 20 min, the 
silk thread was removed from the shunt tube, and its wet weight was immediately measured. The dry weight 
of the thread was measured 6 h later at room temperature. The wet and dry weights of the formed thrombi 
were determined by subtracting the pre-experiment weights of the wet and dry 6-cm threads, respectively. 
Data are the mean ± SD, *P < 0.05, ***P < 0.001 and ****P < 0.0001 versus vehicle, n = 6, analyzed by one-way 
ANOVA, followed by the Tukey multiple comparison test.
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and 10.71 ± 2.98 min, respectively, mean ± SD, n = 10) compared with the vehicle group, suggesting that 
ACH-11 confers a low bleeding risk.
Discussion
Snake venoms have been a rich source of novel antithrombotic agents because they contain a variety 
of proteins and peptides that affect thrombosis and hemostasis17–20. The antithrombotic proteins and 
peptides from snake venoms have been extensively characterized over the previous several decades of 
research. Earlier studies have demonstrated that the bioactive peptides released from pro-proteins by 
enzymatic hydrolysis usually have multifunctional characteristics and are easily absorbed, so we aimed 
to discover small antithrombotic bioactive peptides by subjecting snake venom protein to enzymatic 
hydrolysis. The novel antithrombotic peptide named ACH-11 was isolated from Agkistrodon acutus 
venom hydrolysate, with the sequence LTFPRIVFVLG. ACH-11 exhibited both FXa inhibition and 
anti-platelet aggregation activities, and it showed potent antithrombotic activity in vivo in an acute pul-
monary thrombosis model in mice and an arterio-venous shunt thrombosis model in rats. Interestingly, 
this peptide did not prolong bleeding times in mice at an effective antithrombotic dosage, indicating a 
favorable efficacy to bleeding ratio.
FXa is a key component in blood coagulation, and many FXa inhibitors have been isolated from 
animal venom, falling within a molecular mass range of 4–29 kDa, such as Ac-AP-12 (9.1 kDa) from the 
esophageal glands of adult Ancylostoma caninum21, Ruviprase (4423.6 Da) from the venom of Daboia 
russelii russelii22 and tick anticoagulant peptide (6 kDa) from the soft tick Ornithodoros moubata23. ACH-
11, which consists of 11 amino acids with a MW of 1260.77 Da, is the smallest peptide identified from 
a natural source. Thus, it has substantial advantages over larger anticoagulant proteins, including low 
immunogenicity and low production costs.
The FXa inhibitors are classified into two groups: direct and indirect FXa inhibitors7. Direct FXa 
inhibitors are those that inhibit FXa directly, whereas indirect FXa inhibitors inhibit FXa activity with the 
aid of AT-III24. ACH-11 demonstrated direct inhibitory effects on FXa via a mixed model of inhibition, 
indicating that ACH-11 can inhibit free FXa or the complex of S-2222 and FXa, similar to the effect of 
Ruviprase, purified from Russell’s viper venom22, and AduNAP4, purified from the human hookworm25.
The anticoagulant activity of ACH-11 was verified using aPTT ex vivo assays and by examining clot-
ting time of mice in vivo. To investigate whether the coagulation process was altered by ACH-11, we 
measured aPTT and PT to evaluate the intrinsic and extrinsic routes of coagulation, respectively. It was 
observed that treatment with ACH-11 induced an increase in aPTT as compared to the vehicle group, 
while no obvious increase in PT was found. The in vivo clotting time of ACH-11-treated mice was also 
prolonged in a dose-dependent manner.
Figure 7. ACH-11 exhibited a low bleeding risk in mice. Fifteen minutes after the administration of ACH-
11 (1, 3 and 9 mg/kg), aspirin (9 mg/kg for 30 min) and the vehicle, a 3 mm-long tail tip was cut from the 
mice, and the remaining tail was immersed immediately into saline at 37 °C. The accumulated bleeding time 
(including periods of re-bleeding) was recorded over a 20-min period. Data are presented as the mean ± SD 
(n = 10). ****P < 0.0001, **P < 0.01 versus vehicle, analyzed by one-way ANOVA, followed by the Tukey 
multiple comparison test.
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ACH-11 was also a selective platelet aggregation inhibitor, as it inhibited ADP and U46619-induced 
rabbit platelet aggregation but did not inhibit collagen and thrombin-induced platelet aggregation. A large 
amount of clinical data26 have shown that the combination of antiaggregatory (e.g., acetylsalicylic acid 
or ticlopidine) and anticoagulant agents (e.g., warfarin or heparin), as well as combinations of thrombin 
or FXa inhibitors with GPIIb/IIIa antagonists, has an additive effect by suppressing both blood coag-
ulation and platelet aggregation. Thus, this treatment is more effective than treatment directed against 
coagulation system or platelets alone27,28. ACH-11, a natural bioactive peptide possessing anti-FXa and 
antiaggregatory activities in a single molecule, may have substantial advantages over combination ther-
apies, including greater efficacy in vivo and more predictable and less complex pharmacokinetics and 
pharmacodynamics.
In vivo antithrombotic effects of ACH-11 were observed in an acute pulmonary thrombosis model in 
mice and an arterio-venous shunt thrombosis model in rats. Pulmonary thrombosis is a common model 
in which platelet activator is injected into mice to cause formation of thrombi. This model is character-
ized by the massive activation of circulating platelets and the widespread formation of platelet thrombi 
in microcirculation in the lungs, leading to disseminated pulmonary microembolism and paralysis or 
death of the mice29. The arterio-venous shunt model produces a mixed thrombus of platelets and fibrin, 
in which both the coagulation cascade and the activation of platelets are determinants of thrombus for-
mation. Developing thrombi in this model contain large platelet aggregation that adheres to the throm-
bogenic silk thread, surrounded by erythrocytes and fibrin30,31. ACH-11 exhibited a large antithrombotic 
effect in vivo in these two models, more so than in the anti-platelet aggregation assay in vitro. Provided 
that the average blood volumes of a 200 g rat and 20 g mouse were 15 mL and 2 mL, respectively, ACH-
11 administered at 3 mg/kg produced a concentration of approximately 0.04 and 0.03 mg/mL in rat and 
mouse peripheral blood, respectively. Compared with in vitro data, it is noteworthy that ACH-11 inhibi-
tion of platelet activity in vivo was more potent than when incubated with rabbit PRP, in which ACH-11 
at a concentration of 0.1 mg/mL inhibited ADP-induced platelet aggregation by 32.82%. The effective 
concentration affecting anti-platelet aggregation in vitro was higher than that in systemic circulation in 
the animal model, further confirming that ACH-11 not only inhibited platelets but also affected other 
pathways of thrombosis.
Thrombosis-associated disorders such as cardiovascular disease are a leading cause of mortality 
throughout the world32. Unfortunately, many antithrombotic drugs are associated with side effects, 
which primarily manifest as bleeding complications. At a dose of 3 mg/kg, ACH-11 demonstrated strong 
antithrombotic activity without a significant bleeding risk. Similar results were observed after combined 
therapy with direct FXa inhibitors and anti-platelet agents33,34. For example, the combination of apixaban 
and aspirin reduced the formation of occlusive arterial thrombosis with only a small increase in bleeding 
time35. We also tested the thrombin inhibitory activity of ACH-11, and our results showed that it had no 
inhibitory effect on the amidolytic activity of thrombin (data not shown). As ACH-11 selectively inhibits 
FXa amidolytic activity without affecting the function of thrombin in the circulation system, it should 
have a minimal impact on normal hemostatic response and regulation processes. The activation of the 
GPIIb/IIIa receptor is the common pathway for platelet aggregation, and many of its antagonists exhibit 
a severe bleeding risk. A GPIIb/IIIa-fibrinogen binding assay showed that ACH-11 was not an antagonist 
of GPIIb/IIIa (data not shown).
In conclusion, ACH-11 is a novel antithrombotic peptide isolated from Agkistrodon acutus venom 
hydrolysate. ACH-11 combines FXa inhibitory and anti-platelet activities into a single molecule, show-
ing potent antithrombotic activity in vivo without an obvious bleeding risk. The mechanism of ACH-11 
inhibition of platelet aggregation and its pharmacokinetics and pharmacodynamics in vivo are under 
investigation.
Methods
Preparation of Agkistrodon acutus venom hydrolysates. Agkistrodon acutus venom (0.4 g) was 
dissolved in 10 mL of 0.1 M phosphate buffer solution (PBS) (when using neutrase, papain and alcalase) 
or 0.1 M Glycine-HCl solution (when using pepsin). Then, it was hydrolyzed for 12 h using neutrase at 
pH 8.0 at 50 °C, alcalase at pH 8.0, 50 °C, pepsin at pH 2.0, 37 °C and papain at pH 6.0, 37 °C with a 
total enzyme dose of 1%15. Aliquots of each hydrolysate were collected at 1 h, 2 h, 3 h, 4 h, 8 h and 12 h 
and were boiled for 10 min to stop the reaction. The final hydrolysates were centrifuged at 10,000 rpm 
for 10 min, and the supernatants were freeze-dried.
Anticoagulant peptide purification. The lyophilized neutrase hydrolysate (0.2 g) was dissolved in 
10 mL of distilled water and applied to a Sephadex G-50 column (2.6 × 100 cm) equilibrated with distilled 
water and eluted with the same buffer at a flow rate of 0.6 mL/min. The eluents were monitored at 280 nm 
and were collected at 6 min intervals. The fractions were tested for FXa inhibitory activity. The fraction 
that showed the strongest FXa inhibitory activity was further separated by RP-HPLC on a Lichrospher 
C18 column (20 × 250 mm; Hedera, China) under linear gradient elution conditions using acetonitrile as 
the organic modifier and trifluoroacetic acid (TFA) as the volatile buffer. Eluent A was consisted of 0.1% 
TFA in 10% acetonitrile (v/v), and eluent B consisted of 0.1% TFA in 90% acetonitrile (v/v). Gradient 
elution was carried out according to the following process: 0–15 min, B 10%, and 10–60 min, B 10–30%. 
The flow rate was 7 mL/min. The UV absorbance was monitored at 214 nm. The fractions were tested for 
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FXa inhibitory activity, and the fraction that showed the strongest FXa inhibitory activity (fraction C4) 
was pooled and lyophilized.
Inhibition of amidolytic activity of FXa. Inhibition of the amidolytic activity of FXa was analyzed 
by a method described previously, with minor modifications36. Enzymatic activity was measured in PBS 
at pH 8.34 using the chromogenic substrate method. Freeze-dried samples were dissolved in distilled 
water at a concentration of 5 mg/mL. The sample in 10 μ L was added to 50 μ L of 1 nM enzyme solution 
(FXa) and preincubated at 37 °C for 30 min. The reaction was initiated by the addition of 40 μ L of 300 μ M 
S-2222 substrate solution that was preincubated at 37 °C, and the color was monitored continuously at 
405 nm using Powerwave XS (Biotek, USA) for 20 min. The absorbance-time curve and the slope of the 
curve (Vi) were used to represent the activity of the enzyme. Distilled water served as a control (the slope 
of curve V0). The inhibitory effect was calculated according to equation (1):
VInhibitory rate V V 100 1i0 0(%) = ( − )/ × ( )
where V0 represents the slope of the vehicle and Vi represents the slope of the samples.
Determination of molecular mass and peptide sequence. The molecular mass and amino acid 
sequence of the purified peptide were determined by electrospray ionization-tandem mass spectrometry 
(ESI-MS/MS) on an Agilent 6520 accurate-mass Q-TOF mass spectrometer (Agilent, USA) equipped 
with an electrospray ion source in positive ion mode. The freeze-dried sample obtained by RP-HPLC was 
dissolved in distilled water containing 5% DMSO. The solution was injected continuously, and the setting 
parameters were 40 psi ESI nebulizer gas (N2) pressure, 8.00 L/min ESI drying gas flow rate operating on 
positive mode with a capillary voltage of 4000 V and capillary temperature of 350 °C, and a fragmentor 
voltage of 120 V. The MS/MS spectra were acquired in the data-dependent mode, in which collision 
energy was 70 V. Positive ion intensities were recorded over a mass range (m/z) of 100–1700. A de novo 
peptide sequencing method was performed by a manual calculation.
Peptide synthesis. Solid-phase peptide synthesis was performed according to the method described 
previously37 (supplementary information).
Animals. Institute of Cancer Research (ICR) mice (18–22 g), Sprague-Dawley rats (180–250 g) and New 
Zealand white rabbits (2–2.5 kg) were purchased from Nanjing Qinglongshan Animal Center (Jiangsu 
province, China). They were housed in a temperature-controlled room at 25 ± 2 °C and 50 ± 5% relative 
humidity with a l2 h dark/light cycle. They were given free access to food and water ad libitum. The 
animals were acclimatized for at least 1 week prior to use. All experiments were carried out in accord-
ance with the guidelines and the regulations of the Ethical Committee of the China Pharmaceutical 
University. The protocols were approved by the Institutional Animal Care and Use Committee of the 
China Pharmaceutical University.
In vitro platelet aggregation assay. In vitro platelet aggregation assays were performed accord-
ing to the turbidimetric method, as described previously37. Sample solutions of ACH-11 were tested at 
concentrations of 200, 400, 600, 800 and 1,000 μ g/mL. DMSO (5%) served as the vehicle. The extent of 
platelet aggregation inhibition by ACH-11 was calculated by the following formula (2):
X YPlatelet aggregation inhibition rate [ X] 100 2(%) = ( − )/ × ( )
where X represents the maximum aggregation rate of 5% DMSO-treated PRP and Y represents the 
maximum aggregation rate of sample-treated PRP. IC50 was defined as the drug concentration required 
to inhibit platelet aggregation by 50%.
Determination of the inhibitory constant for FXa. Enzyme kinetic activity was assayed as 
described earlier, with minor modifications38. All enzymatic reactions were carried out in PBS at pH 
8.34 and at 37 °C. Freshly prepared FXa at a constant concentration of 1 nM was used in each reaction. 
ACH-11 was dissolved in 5% DMSO. Activities were measured for 4 different fixed concentrations of 
substrate (73.5, 147, 294 and 588 μ M) in different concentrations of ACH-11 (0, 5 and 10 μ M). The rates 
of the enzymatic reactions were monitored at 405 nm for 20 min using the Powerwave XS (Biotek, USA).
ADP-induced acute pulmonary thrombosis in mice. ADP-induced acute pulmonary thrombosis 
in mice was performed as described previously37. Sixty ICR mice (18–22 g) were fasted overnight and 
randomly divided into 6 groups, with 10 mice per group (males and females in half). The mice were intra-
venously injected with ACH-11 at doses of 0.33, 1 and 3 mg/kg, aspirin (20 mg/kg) or with the vehicle.
In vivo arterio-venous shunt thrombosis. Antithrombotic activity of ACH-11 in vivo was deter-
mined in a rat arterio-venous shunt thrombosis model as described previously39 with a minor modification. 
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Sprague-Dawley rats were weighed and randomized into 5 groups (6 rats per group), including a vehicle 
group, a reference drug group (20 mg/kg of aspirin-treated), and three sample groups (0.33, 1 and 3 mg/
kg of ACH-11-treated, 5 mL/kg). Rats were anesthetized by chloral hydrate (350 mg/kg, i.p.), and an 
arterio-venous shunt tube was installed between the right carotid artery and the left jugular vein40,41. The 
polyethylene tube (12 cm; containing 10-cm long of 4 braided silk thread) was filled with a heparin saline 
solution (25 IU/mL) prior to installation. After blood circulation through the shunt tube for 20 minutes, 
both ends of the tube were pinched, and the silk thread was removed from the shunt tube. Its wet weight 
was measured immediately. The dry weight of thread was measured 6 h later at room temperature. The 
wet and dry weights of the thrombi were determined by subtracting the pre-experimental weights of the 
wet and dry 6-cm threads, respectively.
Ex vivo coagulation parameters. Rat grouping, dosage and administration in this assay were the 
same as in the arterio-venous shunt thrombosis experiments. Fifteen minutes after the administration of 
ACH-11 (0.33, 1 and 3 mg/kg) or saline, blood was take n from the inferior vena cava, and plasma was 
then obtained by centrifuging at 2,000 g for 10 min at room temperature in order to measure PT and 
aPTT. The coagulation parameters were determined by routine laboratory assays using an automated 
coagulation analysis instrument (Coatron M4, TECO GmbH, Germany). For the measurement of aPTT, 
50 μ L of plasma was preincubated for 5 min at 37 °C, and 50 μ L of aPTT reagent was then added and 
incubated for another 5 min, followed by the addition of 50 μ L of 25 mM CaCl2 solution. To measure 
PT, 50 μ L of plasma was preincubated for 5 min at 37 °C, which was followed by the addition of 100 μ L 
prothrombin reagent. The coagulometer was started, and time to clot formation was recorded.
Clotting time in vivo. Whole blood clotting time (CT) in mice was measured by a capillary glass 
tube method as described previously42. Mice were randomly divided into four groups (both sexes, 10 
per group). Three groups were i.v. injected with 0.33, 1 and 3 mg/kg body weight of ACH-11 for four 
consecutive days. The other group received the same volumes of the vehicle.
Bleeding time. Bleeding time of the mice was measured by a tail cutting method as described pre-
viously42. Mice were randomly divided into five groups (both sexes, 10 per group), including a vehicle 
group, a reference drug group (9 mg/kg of aspirin-treated) and three sample groups (1, 3 and 9 mg/kg 
of ACH-11-treated).
Statistical analysis. The data are expressed as the mean of the replicate determinations and the 
standard deviation (SD) or standard error of measurement (SEM). Statistical significance was evaluated 
using ANOVA, followed by Tukey’s test for multiple comparisons. Differences between groups were 
analyzed by Fisher’s test for pulmonary thrombosis. The data were analyzed using GraphPad Prism 5 
(GraphPad Software, Inc., La Jolla, CA, USA).
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